COLLABORATE El Meu Clínic . This link opens in a new tab.
Search
COLLABORATE El Meu Clínic . This link opens in a new tab.
Navigation thread
Clínic Barcelona

Dr. Ignacio Revuelta explains his translational research in posttransplant neoplasia during an IDIBAPS In-House Seminar

The Translational Research group in Posttransplant Neoplasia, led by Dr. Ignacio Revuelta, started up at the IDIBAPS in January 2012. After his stay at Harvard Medical School in Boston, he was incorporated to IDIBAPS and Hospital Clínic in Jannuary 2012 within the clinical / research programme called “50/50”. This original programme is aimed to promote the research activity of skilled clinicians, and will have a direct impact in clinical practice. During his IDIBAPS In-House Seminar presentation, Dr. Revuelta exposed the problem of posttransplant neoplasia and the role of mTOR inhibitors in this process. Dr. Ramon Gomis, director of IDIBAPS, presented the event.

Cancer is the second leading cause of mortality in general and transplant population, and cancer rates are higher after kidney transplantation compared with the general population. Several pathogenic factors have been implicated in oncogenesis and metastasis development in transplant patients, such as the direct secondary effects of exposure to immunosuppressive drugs. The use of mTOR inhibitors as immunosuppressive therapy with antioncogenic, antiproliferative and antiangiogenic properties plays a crucial role in the development of posttransplant neoplasms, tumoral progression, and the potential for metastasis.

The group led by Dr. Revuelta has been studying and characterizing the different behavior of posttransplant neoplasia. However, knowledge about the understanding of oncogenesis and metastasis development in this particular population is still unresolved, and information on long-distance communication between a tumor and the host organs is unknown.

Learn about the next IDIBAPS Seminars 2013.